Cat. No. 5951
Chemical Name: 2-[(2-Chloro-4-fluorophenyl)methyl]
Biological ActivityPotent LXR agonist (IC50 values are 24 and 179 nM for LXRβ and LXRα, respectively). Reduces total serum cholesterol and LDL cholesterol, and inhibits lesion growth in models of atherosclerosis. Increases ABCA1 and ABCG1 mRNA levels in rat peripheral blood cells. Orally bioavailable.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Quinet et al (2009) LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J.Lipid Res. 50 2358. PMID: 19318684.
DiBlasio-Smith et al (2008) Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J.Transl.Med. 6. PMID: 18925943.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses WAY 252623 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: WAY 252623, supplier, LXR, liver, X, receptor, alpha, beta, LXRa, LXRb, β, α, potent, agonists, agonism, orally, bioavailable, Tocris Bioscience, LXR-like Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonist
November 12 - 16, 2016
San Diego, CA, USA